
Opinion|Videos|January 5, 2026
Use of Xanomeline/Trospium in Clinical Practice
Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.
Advertisement
Episodes in this series

Panelists discuss how clinicians are beginning to integrate xanomeline/trospium into practice for patients who have struggled with traditional therapies. They share early observations of improved engagement and cognitive clarity.
Panelists discuss how appropriate patient selection, titration, and adverse effect monitoring are key to maximizing outcomes.
Panelists discuss how broad adoption depends on payer coverage and growing real-world data validating long-term safety and effectiveness.
Advertisement
Related to this article

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
FDA Approves First Heart Valve to Keep Pace With Children's Growth
3
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5

